Malignant mesothelioma, which can be caused by exposure to asbestos, often has a poor prognosis. Now, data from a phase III randomized controlled trial show that the addition of the anti-VEGF monoclonal antibody bevacizumab to the existing standard-of-care chemotherapy regimen significantly improves overall survival. Of note, however, treatment with bevacizumab did increase the risks of grade 3 or higher hypertension and thrombotic events compared with standard-of-care regimens.